Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Pope

Showing results (61-70 of 167) with videos related to

Pageof 17
Sort By:
Advances in Therapy|April 17, 2020
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-AnalysisJanet Pope, Ruta Sawant, Namita Tundia, et al.
Current Rheumatology Reviews|December 14, 2020
Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative DatabaseElliot Hepworth, Mohammad Movahedi, Emmanouil Rampakakis, et al.
The Journal of Rheumatology|August 17, 2018
Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus ErythematosusStephanie O Keeling, Ben Vandermeer, Jorge Medina, et al.
Rheumatology (Oxford, England)|November 22, 2022
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumabErnest Choy, Vivian Bykerk, Yvonne C Lee, et al.
ISRN Rheumatology|March 6, 2012
Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP ImprovesDéanne Malenfant, Kelly Summers, Shannon Seney, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
Rheumatology (Oxford, England)|June 23, 2016
Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis CohortCarol A Hitchon, Gilles Boire, Boulos Haraoui, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Clinical Rheumatology|January 15, 2015
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsDavid Grabowski, Bradley Henderson, Dennis Lam, et al.
RMD Open|July 28, 2023
Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic reviewEric L Matteson, Marco Matucci-Cerinic, Michael Kreuter, et al.
Pageof 17

Showing results (61-70 of 167) with videos related to

Sort By:
Pageof 17
Advances in Therapy|April 17, 2020
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-AnalysisJanet Pope, Ruta Sawant, Namita Tundia, et al.
Current Rheumatology Reviews|December 14, 2020
Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative DatabaseElliot Hepworth, Mohammad Movahedi, Emmanouil Rampakakis, et al.
The Journal of Rheumatology|August 17, 2018
Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus ErythematosusStephanie O Keeling, Ben Vandermeer, Jorge Medina, et al.
Rheumatology (Oxford, England)|November 22, 2022
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumabErnest Choy, Vivian Bykerk, Yvonne C Lee, et al.
ISRN Rheumatology|March 6, 2012
Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP ImprovesDéanne Malenfant, Kelly Summers, Shannon Seney, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
Rheumatology (Oxford, England)|June 23, 2016
Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis CohortCarol A Hitchon, Gilles Boire, Boulos Haraoui, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Clinical Rheumatology|January 15, 2015
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsDavid Grabowski, Bradley Henderson, Dennis Lam, et al.
RMD Open|July 28, 2023
Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic reviewEric L Matteson, Marco Matucci-Cerinic, Michael Kreuter, et al.
Pageof 17